Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether the use of a very low protein diet is effective in delaying the start of chronic dialysis treatment in patients affected by chronic kidney disease (CKD).


Clinical Trial Description

The prevalence of chronic dialysis patients is increasing worldwide because of the rising incidence of end stage renal disease, it is burdened by high cardiovascular risk, it is associated with a very high morbidity and mortality and it determines enormous costs for the community.

The improvement in the management of metabolic and cardiovascular complication associated to chronic kidney disease (CKD) since the early stages of the disease becomes mandatory in order to delay the start of dialysis and to ameliorate the whole patient outcome.

Dietary protein restriction represents a basic therapeutic approach in CKD, by reducing the accumulation of nitrogen catabolic substances, the phosphorus retention and the consequent hyperparathyroidism, the metabolic acidosis, the salt intake and the consequent hypertension, the proteinuria, and by improving the anemia and the glycemic tolerance, but the effects of the low protein diet on renal failure progression rate have not been definitely demonstrated.

Dietary effective reduction of just 0.2 g/kg/day of proteins is effective in ameliorating blood urea nitrogen, metabolic acidosis and hyperphosphoremia, and the very low protein diet (VLPD) allows a further improving of the metabolic control of uremia, it is safe, not affecting the nutritional status, and it is cost saving. VLPD has been suggested to delay the start of renal replacement therapy with respect to standard low protein diet, by mean of either secondary analysis of clinical trials or retrospective analysis.

Large randomized clinical trials (RCT) on this issue lack, and the effect of VLPD on renal death remain to be addressed. As well, information on patients' compliance to VLPD prescription and on the impact of VLPD on the quality of life are needed. Finally, also the effects of VLPD on both cardiovascular risk factors and mortality remain to be completely evaluated.

The primary aim of this study is to evaluate, by mean of a RCT, the effect of the very low protein diet on the renal death in renal patients affected by chronic renal insufficiency of moderate to advanced degree (CKD stages 4 and 5). Secondary aims are to evaluate the effect of VLPD on cardiovascular risk factors, morbidity and mortality, the adherence to VLPD, and the relationship between VLPD and quality of life. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00323713
Study type Interventional
Source Azienda Sanitaria ASL Avellino 2
Contact
Status Active, not recruiting
Phase N/A
Start date February 2005
Completion date December 2012

See also
  Status Clinical Trial Phase
Completed NCT00968877 - Vitamin D and Chronic Renal Insufficiency Phase 3
Terminated NCT00701714 - Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients Phase 3
Completed NCT00998972 - N-acetyl-cysteine (NAC) and Kidney Graft Function Phase 3
Completed NCT00716573 - Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure Phase 4
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT02203084 - Social Determinants in Chronic Disease in British Columbia N/A
Recruiting NCT02147782 - Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
Completed NCT01029002 - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease Phase 3
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00095056 - An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) Phase 3
Completed NCT00223548 - MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application Phase 2
Completed NCT01574157 - Investigations of the Optimum Serum Bicarbonate Level in Renal Disease. N/A
Active, not recruiting NCT02751099 - Bone and Cardiovascular Disease After Kidney Transplant
Recruiting NCT02002585 - Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease Phase 2
Completed NCT01252810 - Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure Phase 2
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Completed NCT00792857 - Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) Phase 1
Completed NCT00888069 - Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects Phase 1
Completed NCT00369733 - STAAR-3 Clinical Study Phase 4
Recruiting NCT06362759 - A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP Phase 2